LONGEVITY & CELLULAR HEALTH / FAQ
Questions From the Literature
Direct, citation-anchored answers to what readers most often want to know about NAD+ and MOTS-c.
What is NAD supplement used for?
In research and the supplement market, NAD+ precursors — primarily NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — are studied and sold for their ability to raise blood NAD+ levels, which decline with age. The rationale is that higher NAD+ supports the enzymes (sirtuins, PARPs) that govern DNA repair, metabolic regulation, and stress responses [4]. One human RCT also showed improved muscle insulin sensitivity with NMN [3]. Whether raised blood NAD+ translates to clinical health benefits in people remains genuinely uncertain; a 2025 review concluded human efficacy data are still limited [1].
What is the downside of taking NAD+?
Several downsides are documented in the literature. IV NAD+ infusions can cause flushing, chest tightness, and abdominal discomfort if run too fast; a compounded injectable NAD+ product was subject to an FDA Class I recall for elevated bacterial endotoxin. NMN's supplement status is contested — the FDA has raised a challenge to its dietary-supplement classification. Oral NAD+ capsules (not precursors) are likely ineffective as NAD+ delivery, since cells cannot transport the intact dinucleotide easily. A theoretical concern exists that boosting NAD+ could support existing cancer cell metabolism, given NAD+'s context-dependent roles in oncology [4]. Supplement-grade products vary widely in purity and verified content [1].
Is it safe to take NAD daily?
The human RCT data for oral NMN (up to 900 mg/day for 60 days) and oral NR (up to 1000 mg/day for 8 weeks) both reported no significant adverse events compared to placebo, no flushing with NR at any dose, and no dose-limiting toxicities [2][5]. Those are the best available controlled human safety data. They do not, however, constitute long-term safety assessments, they used specific formulations, and they say nothing about IV or injectable NAD+, which carries different risk considerations. This site does not advise on supplementation; consult a clinician for guidance on personal use.
Does NAD cause weight gain?
The published human trials do not show weight gain as an effect of NMN or NR supplementation. The multicenter NMN RCT reported that the biological-age measure did not increase, and no weight-gain signal appeared in any dose group [2]. The NR trial in overweight adults found no significant changes in LDL cholesterol or metabolic markers beyond NAD+ elevation [5]. Neither NMN nor NR is known to cause weight gain, though neither is studied as a weight-loss intervention either. The relationship between NAD+ and body composition in humans is an open research question.
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA. Its primary action is to activate AMPK — a master cellular energy sensor — by inhibiting the folate cycle and de novo purine biosynthesis. In aged mice, MOTS-c significantly improved physical performance (running capacity, grip strength, gait) [11]. Under metabolic stress it moves from the mitochondrion to the nucleus to regulate antioxidant and metabolic gene expression [12]. A 2024 study identified casein kinase 2 (CK2) as its direct binding target in skeletal muscle [8]. In humans, lower circulating MOTS-c has been associated with worse mortality and cardiovascular outcomes in a hemodialysis cohort [9] — but no interventional human trials have been completed.
What are the negative side effects of MOTS-c?
There are no completed human safety or efficacy trials for exogenous MOTS-c, so a human side-effect profile does not exist in the peer-reviewed literature [10]. The research-chemical supply chain is unregulated, meaning product purity and sterility are not guaranteed by pharmaceutical standards. MOTS-c is prohibited in elite sport, creating a legal and career consequence for tested athletes [9]. Some published work notes that MOTS-c effects may differ across ancestries and genotypes (a pro-diabetogenic mtDNA variant affecting MOTS-c has been described), suggesting effects may not be uniform [10]. In the absence of human trial data, the honest answer is that the side-effect profile is unknown.
Is MOTS-c legal to buy?
In most jurisdictions, MOTS-c can be purchased as a research chemical for laboratory use, sold by chemical suppliers without a prescription. However, it is not legal for human use as an approved drug or dietary supplement, and its use is not regulated. In the anti-doping context, it is prohibited by WADA and USADA for athletes in competition and out of competition — purchase and use by a competitive athlete would risk a doping sanction regardless of retail legality [9]. This desk does not advise on purchasing or use.
How often do you inject MOTS-c?
This desk does not provide dosing or injection schedules. No validated human pharmacokinetics exist for MOTS-c — there is no published measured half-life, bioavailability, or dose-response in humans — so any protocol circulating in research communities is derived from animal studies (typically 0.5–15 mg/kg in mice) with no clinical validation behind it [10]. Rodent doses cannot be extrapolated to humans. MOTS-c is a research chemical for laboratory use only, not an approved human therapeutic. Consult a physician before considering any experimental compound use; this site is a literature digest, not a clinical resource.
What is the difference between NAD+ and NMN?
NAD+ (Nicotinamide Adenine Dinucleotide) is the active coenzyme inside cells. NMN (Nicotinamide Mononucleotide) is a precursor — a molecule cells convert into NAD+ through their own biosynthetic machinery. The distinction is practically important: cells cannot easily import intact NAD+ from outside, but they can import NMN and build NAD+ from it. Human RCTs demonstrating blood NAD+ elevation and metabolic effects have been conducted with NMN and NR as the administered substance, not NAD+ itself [2][3][5]. "NAD+ supplements" that contain the dinucleotide directly may have limited efficacy as NAD+ delivery vehicles compared to precursor-based approaches [1].
Why does NAD+ decline with age?
The strongest mechanistic explanation is the rise of CD38 — an ectoenzyme that degrades NAD+ as part of calcium signaling and immune function. CD38 activity increases with age, driven partly by age-related inflammation, and mice engineered without CD38 are protected against the age-related NAD+ decline: they maintain SIRT3 activity, better mitochondrial function, and healthier metabolic profiles into old age [6]. Alongside CD38, PARP1 activity — triggered by accumulated DNA damage — consumes NAD+ and may further deplete the pool in older tissues [4]. This dual-drain mechanism (CD38 rising, DNA damage increasing) makes NAD+ decline a complex target, not simply resolvable by supplementing a single precursor.
Does MOTS-c have anything to do with exercise?
Yes, in an interesting way. MOTS-c is induced by exercise — endogenous MOTS-c rises in skeletal muscle and circulation after physical activity across all age groups studied in mice [11]. This has led researchers to propose it as an "exercise-mimetic mitokine," a signaling molecule that may mediate some of exercise's metabolic benefits. That framing requires caution: mimicking a signal is not equivalent to the full physiological response to exercise, and no human trial has shown that exogenous MOTS-c replicates exercise benefits. But the exercise-inducibility does connect MOTS-c biology directly to one of the best-documented interventions for healthy aging [11].
Can NAD+ and MOTS-c be studied together?
As a research question, their combination is scientifically coherent: NAD+ supports the mitochondrial energy state that MOTS-c responds to, and both feed into AMPK signaling — NAD+ via sirtuin-AMPK crosstalk, MOTS-c via its folate-cycle mechanism [4][10]. In the lab, studying them in combination would probe whether the two mechanisms are additive or redundant. In humans, no such combination trial exists, and this desk does not speculate about combined use. The comparison page details each molecule's evidence base separately.